PCSA MEXC RealStocks
Own real PCSA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 05:04:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Processa Pharmaceuticals, Inc. (PCSA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.71, with a market capitalization of $4.81M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.04 to $8.88. This page covers its latest market performance, valuation, price trends and company information.
$4.81M | |
$1.70 | |
$1.79 | |
$1.43 | |
$1.73 | |
29.69K | |
80.39K | |
-- | |
$8.88 | |
$1.04 | |
-- | |
2026-09-30 |
Processa Pharmaceuticals, Inc. (PCSA) last closed at $1.71 as of 2026-11-19 00:31:00, up 0.76% ($0.01) from the previous close of $1.73.
During the latest regular trading session, PCSA traded between $1.43 and $1.79, with a volume of 29.69K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Processa Pharmaceuticals, Inc. (PCSA) moved from $1.95 to $1.71, representing a decline of 12.10% ($0.24).
The stock traded between $1.43 and $1.95 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 26.39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 8.6%
PCSA is currently trading at $1.71, placing it 8.6% of the way from its 52-week low of $1.04 to its 52-week high of $8.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Processa Pharmaceuticals, Inc. (PCSA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PCSA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PCSA shares and USD.
PCSA Shares to USD
1.00 PCSA shares = 1.714 USD
Calculations are estimates based on the latest available price and are for reference only.